Interventional Management of Stroke Trial: A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV rt-PA (Activase) Alone When Initiated Within Three Hours of Acute Ischemic Stroke Onset.

Next Previous
Trial Profile

Interventional Management of Stroke Trial: A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV rt-PA (Activase) Alone When Initiated Within Three Hours of Acute Ischemic Stroke Onset.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Alteplase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMS-III

    • Most Recent Events

    • 28 Apr 2017 Results of a pooled analysis in patients from three randomised trials (NINDS IV tPA, IMS-III, ALIAS part 1 and 2), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results (n=438) assesing benefits of ultra-early statin use after thrombolytic treatment, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 20 Oct 2015 Results published in the Stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top